Navigation Links
GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
Date:4/16/2009

New company's product portfolio and pipeline

     Combined Marketed Product Portfolio      Combined Clinical Development
                                               Pipeline
    Product              Class                Product       Class        Phase
    Agenerase            Protease inhibitor   GSK 1349572   Integrase       II
                                                             inhibitor
    Combivir             NRTI                 UK-453061     NNRTI           II
    Epivir/3TC           NRTI                 GSK 2248761   NNRTI           II
                                               (IDX899)
    Epzicom/Kivexa       NRTI                 PF-232798     CCR5
                                                             antagonist     II
    Lexiva/Telzir        Protease inhibitor   PF-3716539    PK enhancer      I
    Rescriptor           NNRTI (US only)      GSK706769     CCR5 antagonist  I
    Retrovir/AZT         NRTI
    Selzentry/Celsentri  CCR5 antagonist
    Trizivir             NRTI
    Viracept             Protease inhibitor
                          (N. America only)
    Ziagen               NRTI


Initiatives to improve treatment access

The new company will continue GSK's and Pfizer's commitments to improve access to HIV medicines for everyone.

Not-for-profit pricing for HIV medicines will continue for those countries most in need, and the new company will continue to facilitate new voluntary licences to diversify production and expand capacity in these markets.

The new company will also conduct research and development activities specifically to address appropriate access to HIV medicines in developing countries. In particular, the new company will increase its research effort into treatments and formulations for children living with HIV.

The new company will continue GSK and Pfizer's strong reco
'/>"/>

SOURCE GlaxoSmithKline plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
2. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
3. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
4. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
5. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
6. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
7. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
8. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
9. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
10. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
11. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim is now ... and reduces the appearance of fine lines and wrinkles. , According to the Allergan ... add volume to your cheek area to correct age-related volume loss in adults over ...
(Date:7/28/2015)... ... 28, 2015 , ... On July 16th NPR reported needle exchange ... proposed bills and laws revolving the implementation of a small pilot program in Miami-Dade ... are continuing to hand out clean needles to drug users who are addicted to ...
(Date:7/28/2015)... PAUL, Minn. (PRWEB) , ... July 28, 2015 ... ... workflow company Kinetic Data announced that Schneider Electric has completed its upgrade ... Electric is a global organization with more than 170,000 employees in 134 countries ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard ... authorized the Company, from time to time and depending on market conditions, to ... to $25 million. Repurchases will be made in open market or privately negotiated ...
(Date:7/28/2015)... ... , ... Women fear developing Alzheimer's disease more than having a heart attack ... are treatable, but there is little an individual can do to arrest the progress ... clinical trial, reports the July 2015 Harvard Women's Health Watch . , "There ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that effective with the ... for Pyratine-6(TM), all promotion, sales and distribution of,Pyratine-6(TM) ... Company., Phil Rose, Senetek,s Chief Operating Officer ...
... 1 UTC Power, a United,Technologies Corp. (NYSE: ... Hospital in California,s Napa Valley with its new, next-generation,fuel ... in full,production in the summer of 2009., St. ... of Adventist Health, a not-for-profit health care system operating ...
... RGEN ) announced today that Dr. Alfred L. Goldberg, ... Goldberg is currently a Professor of,Cell Biology at Harvard ... for elucidating the structure and function of the proteasome,which ... in,cells. In addition, he has made major contributions to ...
... increase as women go through menopause according to ... earlier than planned also increases through late perimenopause ... is published in the July 1 issue of ... especially problems staying asleep, are relatively prevalent concerns ...
... direct marketing promotional products company, is tapped in to a network ... products. , ... Lewiston, ME (PRWEB) July 1, 2008 ... on its Web site, Crestline Custom Imprinted Products, a direct marketing ...
... as new surgical procedures are,breaking ground daily in ... breaking ground for patients. LipoVance.com,( http://www.LipoVance.com ) is ... it is offering an unprecedented $800 coupon,toward liposuction ... "In today,s troubled economy," said Kevin Gaines ...
Cached Medicine News:Health News:Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM) 2Health News:St. Helena's Hospital Orders New Model 400kW Fuel Cell From UTC Power 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Sleep problems associated with menopause vary among ethnic groups 2Health News:Crestline Has Access to Hundreds of Thousands of Items 2Health News:The Shape of Things to Come: Website Gives the Lowdown on Liposuction, Pioneers the Field by Offering Consumers $800 Coupons Toward Procedures 2
(Date:7/28/2015)... 28, 2015 Voalte, the leader in ... in purpose-built wireless communications, today announced that Bay ... 104-bed acute-care facility in Webster, Texas ... One™ solution on Spectralink PIVOT™ purpose-built smartphones for ... Voalte a member of its AIMS Partner Program ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Pharmaceutical Industry in China to 2020: ... Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, ... offering. This report tackles not ... China but also home grown companies ...
(Date:7/28/2015)... YORK , July 28, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Human Insulin Market ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore ...
Breaking Medicine Technology:Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3Pharmaceutical Industry in China to 2020: Market to Increase Dramatically to $200 Billion 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: